FDA Inspection
Lilly France S.A.S.Lilly France S.A.S. – FDA Inspection, Apr 4, 2017
Record Details
This FDA Inspection record concerns Lilly France S.A.S., with an inspection on April 4, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- People
- Marie B. Buen-Bigornia (Issuing Officer)
- Zachery L. Miller (FDA Associated Person)
View Company Profile
ID · e5ccc457-4508-4a84-a212-24a4fa072cb5
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1020863
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Lilly France S.A.S.
8| Date | Classification | Office | Project area |
|---|---|---|---|
| September 29, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 15, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 16, 2020 | NAI | Center for Devices and Radiological Health | Postmarket Assurance: Devices |
| February 19, 2019 | VAI | Office of Inspections and Investigations | New Drug Evaluation |
| August 28, 2018 | Not classified | Office of Inspections and Investigations |
Other documents for Lilly France S.A.S.
- FDA Inspection 1299456 - 2023-09-29
- FDA Inspection 1180181 - 2021-01-15
- FDA Inspection 1117961 - 2020-01-16
- FDA Inspection 1081382 - 2019-02-19
- FDA Inspection 1063854 - 2018-08-28
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.